191 related articles for article (PubMed ID: 23675882)
1. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
Galic V; Coleman RL; Herzog TJ
Curr Cancer Drug Targets; 2013 Jul; 13(6):698-707. PubMed ID: 23675882
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer.
Colombo PE; Fabbro M; Theillet C; Bibeau F; Rouanet P; Ray-Coquard I
Crit Rev Oncol Hematol; 2014 Feb; 89(2):207-16. PubMed ID: 24071502
[TBL] [Abstract][Full Text] [Related]
3. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
4. SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.
Fukumoto T; Magno E; Zhang R
Mol Cancer Res; 2018 Dec; 16(12):1819-1825. PubMed ID: 30037854
[TBL] [Abstract][Full Text] [Related]
5. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
6. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
7. New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications.
Gadducci A; Guerrieri ME; Genazzani AR
Gynecol Endocrinol; 2012 Aug; 28(8):582-6. PubMed ID: 22304686
[TBL] [Abstract][Full Text] [Related]
8. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
9. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
10. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
11. Akt activation by Ca
Gocher AM; Azabdaftari G; Euscher LM; Dai S; Karacosta LG; Franke TF; Edelman AM
J Biol Chem; 2017 Aug; 292(34):14188-14204. PubMed ID: 28634229
[TBL] [Abstract][Full Text] [Related]
12. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Stordal B; Timms K; Farrelly A; Gallagher D; Busschots S; Renaud M; Thery J; Williams D; Potter J; Tran T; Korpanty G; Cremona M; Carey M; Li J; Li Y; Aslan O; O'Leary JJ; Mills GB; Hennessy BT
Mol Oncol; 2013 Jun; 7(3):567-79. PubMed ID: 23415752
[TBL] [Abstract][Full Text] [Related]
13. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
[TBL] [Abstract][Full Text] [Related]
14. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
Boussios S; Karihtala P; Moschetta M; Abson C; Karathanasi A; Zakynthinakis-Kyriakou N; Ryan JE; Sheriff M; Rassy E; Pavlidis N
Invest New Drugs; 2020 Feb; 38(1):181-193. PubMed ID: 31650446
[TBL] [Abstract][Full Text] [Related]
15. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
16. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
17. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethal approaches to breast cancer therapy.
Rehman FL; Lord CJ; Ashworth A
Nat Rev Clin Oncol; 2010 Dec; 7(12):718-24. PubMed ID: 20956981
[TBL] [Abstract][Full Text] [Related]
19. Targeting signaling pathways in epithelial ovarian cancer.
Smolle E; Taucher V; Pichler M; Petru E; Lax S; Haybaeck J
Int J Mol Sci; 2013 May; 14(5):9536-55. PubMed ID: 23644885
[TBL] [Abstract][Full Text] [Related]
20. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
